The goal of treatment for newly diagnosed multiple myeloma (NDMM) patients is achieving the deepest possible remission, which typically involves aiming for minimal residual disease negativity. Frontline therapy for NDMM is evolving to include novel induction regimens with anti-CD38 antibodies, which have been shown to yield improved depth of response after induction. These new frontline treatments vary in induction regimen composition and use of transplant, consolidation, and maintenance therapy. Patient- and disease-related factors (including high-risk genetics, frailty, and transplant eligibility), as well as treatment-related toxicities, complicate treatment decisions for health care providers (HCPs). In addition, supportive care interventions aimed at minimizing the risk of infection and other treatment-related adverse events (AEs) are critical for maintaining quality of life and ensuring that patients remain on therapy.
- Provider:University of Cincinnati College of Medicine
- Activity Link: https://www.mycme.com/courses/newly-diagnosed-multiple-myeloma-treatment-strategies-9646
- Start Date: 2024-08-30 05:00:00
- End Date: 2024-08-30 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Sanofi - Amount: 155000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Hematology, Internal Medicine, Medical Oncology